Recent studies have reported reversal of chemoresistance using an antisense approach to target Bcl-2 in models of chronic lymphocytic leukemia, non-Hodgkins lymphoma, and multiple myeloma79–82. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.